Microbiome_based_prediction_of_vaccine_response_in_elderly_patients
Four lanes of HiSeq 4000 125bp paired end sequencing will be undertaken multiplexed at 32 samples on each lane. Resulting data will be analysed using the extensive bacterial collection and genomic library. Integration of metagenomic sequencing data and analysis with extensive clinical outcome data will enable identification of key candidate bacteria that could act as biomarkers for vaccine response to reduced efficacy. This will provide the much needed evidence to optimise vaccine responses in this vulnerable age group, with future global health implications.